ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

$16.87 +0.14 (+0.84%)

(As of 12/20/2024 05:15 PM ET)

ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
6

Buy
10

Based on 16 Wall Street analysts who have issued ratings for ACADIA Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 6 have given a hold rating, and 10 have given a buy rating for ACAD.

Consensus Price Target

$25.60
51.75% Upside

According to the 16 analysts' twelve-month price targets for ACADIA Pharmaceuticals, the average price target is $25.60. The highest price target for ACAD is $42.00, while the lowest price target for ACAD is $19.00. The average price target represents a forecasted upside of 51.75% from the current price of $16.87.

Get the Latest News and Ratings for ACAD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors.

ACAD Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$25.60	$25.56	$25.56	$35.71
Forecasted Upside	51.75% Upside	56.15% Upside	56.92% Upside	13.71% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

ACAD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ACAD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ACADIA Pharmaceuticals Stock vs. The Competition

Type	ACADIA Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.63	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	51.75% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent ACAD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/7/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00	+70.99%
11/7/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00	+77.33%
10/10/2024	Raymond James 4 of 5 stars	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$30.00 ➝ $23.00	+48.67%
8/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$25.00 ➝ $23.00	+49.45%
8/7/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$37.00 ➝ $28.00	+82.17%
The #1 Coin for November 2024 (Ad) Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now…
8/7/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$29.00 ➝ $26.00	+67.31%
8/7/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$28.00 ➝ $20.00	+6.10%
6/27/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$31.00	+100.00%
5/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$26.00 ➝ $22.00	+44.64%
5/9/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$26.00 ➝ $21.00	+30.84%
5/9/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$31.00 ➝ $28.00	+63.46%
5/9/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$25.00 ➝ $21.00	+22.59%
5/6/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $19.00	+11.44%
3/25/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$29.00 ➝ $25.00	+40.53%
2/7/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Outperform ➝ Market Outperform	$42.00	+66.67%
12/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy ➝ Buy	$25.00	+18.54%
8/3/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$39.00 ➝ $38.00	+36.01%
4/28/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$93.00 ➝ $95.00	+363.41%
3/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$22.00 ➝ $25.00	+28.80%
3/14/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$10.00 ➝ $15.00	-22.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:58 AM ET.

ACAD Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ACADIA Pharmaceuticals is $25.60, with a high forecast of $42.00 and a low forecast of $19.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACAD shares.
: According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 51.75% based on their 12-month stock forecasts.
: ACADIA Pharmaceuticals has been rated by research analysts at HC Wainwright, Needham & Company LLC, and Raymond James in the past 90 days.
: Analysts like ACADIA Pharmaceuticals less than other "medical" companies. The consensus rating score for ACADIA Pharmaceuticals is 2.63 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ACAD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

This page (NASDAQ:ACAD) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target